Thank you, John, and good morning, everyone. Let's first address the restatement that was announced on March 19 that was identified as part of the year-end order. The company yesterday filed restated 2024 financial statements as of and for the quarters ended March 31, June 30 and September 30 due to a correction of accounting treatment for a complex Q1 2024 debt transaction. The reason for the restatement revolved around the debt transaction that occurred on January 30, 2024. The transaction was incorrectly treated as debt modification rather than debt extinguishment. Because of this change in accounting treatment, the debt was required to be fair valued quarterly using a Monte Carlo statistical model, the inputs variable include volatility, stock price variability and risk-free rate. Given this, the change in fair value each quarter changed materially, but all of these adjustments are noncash and are excluded in our non-GAAP measures. The full year noncash impact of this treatment and the subsequent exchange to preferred stock resulted in an incremental net loss impact of $106.4 million. This does not impact our shareholders' deficit calculation as the offset to this sits in [APIC], giving a net zero impact on our shareholders' deficit. Important to note, this debt no longer exists on the balance sheet as of December 2024 as it was exchanged into Series A preferred stock for a fair value of $110.3 million. This is a nonrecurring fair value and will not be further fair valued in future quarters. This preferred exchange was part of our plan to deleverage our balance sheet and successfully regain listing compliance with NASDAQ, which occurred in February 2025. In addition to regaining NASDAQ compliance, we have been keenly focused on securing the cash we will need through '25 while we ramp up commercialization. We have seen some great progress on this during Q1. In January 2025, the company conducted further at-the-market offerings in which we issued and sold almost 7.5 million shares for net proceeds of $19.4 million. A portion of the funds enabled us to do the acquisition of SeaTrepid, which will enhance our financial position as we move through 2025. In January '25, we reduced the conversion price of the loans under the January '24 term loan agreement to $1.59, which resulted in subsequent conversions, which further improved the position of our balance sheet. I will now discuss in more detail our financial results for 2024. Revenue for the year was $1.8 million, which is down $4.8 million from '23. The decline in revenue was largely due to the reduction in government contracts in '24. However, in '24, the company did recognize revenue for commercial operations of the Aquanaut vehicle for the first time in the company's history, and we will grow on this throughout 2025. Operating expenses for the year were $24.9 million, which is a $36.8 million improvement from 2023. Excluding nonrecurring costs in '23 of $25.4 million impairment of property and equipment, $2.5 million loss on contract and $1.5 million severance costs, operating expenses dropped $7.4 million year-on-year, primarily due to continued focus on cost control. G&A costs for the year were $13.4 million, which is an improvement of $4.9 million compared to '23. This is primarily due to headcount reductions and a result of dedicated focus on reducing costs and eliminating non-value-added spend. Net loss for the year was $134.9 million. This is an $84.2 million increase from the net loss in '23. This is primarily due to the $127.6 million loss on extinguishment of debt recognized during the year, partially offset by the change in fair value of $21.1 million related to warrant liabilities and debentures and $25.4 million impairment recognized in '23 that did not occur again in '24. Adjusted net loss for the year was $26.1 million compared to $34.3 million for the prior year. This shows an $8.2 million improvement even considering the $4.8 million reduction in revenue year-on-year. Cash at the end of '24 was $1.2 million compared to $0.7 million at the end of '23. This is primarily a result of funding received through debt and equity financing and an at-the-market offering offset by cash used in operations. Last year, we did a lot of work to deleverage and clean up the balance sheet. Throughout the year, we converted debt with a principal value of $35.5 million to preferred stock in December '24. We did take on new debt of $14.3 million in the first half of 2024 and a further $2.1 million with a fair value of $2.5 million in the second half of the year. With these actions, along with the raise through our at-the-market facility during Q1 2025, we are in a strong position in '25 to continue the path of commercialization of the Aquanaut vehicle while staying appropriately funded. I will now pass the call back over to John.